|
|
101 Washington Road, Suite 970
Lake Bluff, IL 60044 USA
phone:847.887.0800
fax:847.887.9281
|
|
| Symbol |
NEOL |
| Exchange |
OTC |
| Founded |
1990 |
| Employees |
20 |
|
|
| info@insysrx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Develops and commercializes of new drugs for various cancers |
|
| Management |
| Martin McCarthy, Corporate Controller; Shahid Ali, Executive Vice President of Research & Development |
| |
|
|
|
|
|
|
|
| Keywords |
| idiopathic pulmonary fibrosis, lung fibrosis, drug pipeline, cancer, neolipid, drug delivery, tumor targeting, Drug Delivery, stem cell, NEOL |
|
|
|
| Description |
|
NeoPharm is engaged in the research, development and commercialization of new drugs for various cancers, other diseases, and therapeutic applications. The company's drug development program includes two proprietary platforms: the tumor-targeting toxin platform and the NeoLipid drug delivery system. |
|
| Products / Services |
NeoPharm uses novel proprietary lipids and improved procedures to entrap difficult-to-deliver drugs in small, homogenous, and stable liposomes, which are microscopic membrane-like structures created from lipids (fats). Because tumor cells need to consume large amounts of fat to sustain their rapid growth, they recognize the liposomal drug as a potential source of nutrition. The company has licensed IL13-PE38 from the NIH, FDA and the University of Michigan as a potential therapeutic agent for the treatment of idiopathic pulmonary fibrosis and asthma. Repeated immune-related damage and scarring destroys the elasticity of the lungs, compromising the patients' ability to breathe and contributing to idiopathic pulmonary fibrosis. Cells initiating the immune response to the lungs over-express IL-13 receptors, so selective destruction of cells presenting IL-13 receptors can reduce further damage and improve lung function. Other current drug product candidates within this platform include LEP-ETU, LE-DT, LE-rafAON, and LE-SN38.
|
|
| Technology / Differentiation |
| NeoPharm uses NeoLipid technology to combine drugs or other compounds in proprietary lipids to create a stable liposomal product. NeoLipid formulations are designed with the goal of producing small and homogenous drug particle size with simple easy-to-use reconstitution of lyophilized (or freeze-dried) products. This is especially important during drug storage, reconstitution and administration to the patient. |
|
| Market / Customers |
Glioblastoma multiformes (GBMs) are the most common type of malignant primary brain tumor in adults. Treatment success has not significantly changed over the last 20 years, with most patients living less than one year after diagnosis despite aggressive surgery, radiation, and chemotherapy.
|
|
| Competitors / Substitutes / Alternatives |
Bristol-Myers Squibb Co., Pfizer Inc., Sanofi-Aventis
|
|
| Status |
| Neopharm has advanced five drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis, or IPF, and asthma. Cash on hand is sufficient to fund anticipated development activities into the second quarter of 2010. The company is interested in venture capital, institutional investor awareness, M&A advisors, and strategic/corporate partnerships. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
